GlassScriptPhysician profile
Edward W Capparelli
NPI 1275504326
$2,982.40
in general payments reported to CMS, 2019-2025
33 companies · $228 in 2025
The $228 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $495 · 2020: $104 · 2021: $489 · 2022: $817 · 2023: $611 · 2024: $239 · 2025: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,078.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,078.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $760.57 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $509.15 | 2021-2024 | Ozempic, Rybelsus |
| Abbvie INC. | $258.20 | 2021-2025 | Vraylar |
| Ucb, INC. | $195.18 | 2019-2023 | Briviact |
| Alkermes, INC. | $163.29 | 2019-2025 | Vivitrol |
| Mdd US Operations, LLC | $142.81 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $129.59 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $83.23 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $68.51 | 2022-2023 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.59 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $60.81 | 2022-2025 | Breztri, Airsupra |
| Biohaven Pharmaceutical Holding Company LTD. | $59.91 | 2022 | |
| Scilex Pharmaceuticals INC. | $41.06 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.69 | 2021-2024 | |
| Uswm, LLC | $40.06 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $30.52 | 2022-2023 | Gvoke Hypopen |
| Averitas Pharma INC. | $29.37 | 2025 | Qutenza |
| Allergan, INC. | $27.52 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.37 | 2025 | Caplyta |
| Pfizer INC. | $26.28 | 2022 | |
| Valeritas, INC. | $25.00 | 2019 | |
| Therapeuticsmd, INC. | $24.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $21.50 | 2019 | |
| Amgen INC. | $18.20 | 2024 | Tavneos |
| Sanofi Pasteur INC. | $18.05 | 2023 | |
| Lundbeck LLC | $17.80 | 2023 | Vyepti |
| Shire North American Group INC | $16.47 | 2019 | |
| Braeburn INC. | $15.08 | 2024 | Brixadi |
| Axsome Therapeutics, INC. | $15.00 | 2024 | Auvelity |
| Astellas Pharma US INC | $14.05 | 2025 | Veozah |
| Agile Therapeutics, INC. | $13.40 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.96 | 2021 | |
| Lilly USA, LLC | $12.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Capparelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.